Arabic Arabic English English French French German German
dark

Medicare seeks comments for Alzheimer’s treatment national coverage policy

Medicare seeks comments for Alzheimer’s treatment national coverage policy
tjordan_drupal
Jul 14, 2021

The Centers for Medicare & Medicaid Services is accepting comments through Aug. 11 on whether to establish a national Medicare coverage policy for monoclonal antibodies to treat Alzheimer’s disease.

The Food and Drug Administration recently approved the first such drug (aducanumab) through an accelerated pathway that requires the company to verify clinical benefit in a post-approval trial. Medicare administrative contractors are currently making coverage determinations for aducanumab at the local level.

Stakeholders may register for CMS webinars July 22 to learn more or comment. CMS plans to release a proposed decision within six months and a final decision within nine months. 

Headline

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

CDC: Drug overdose deaths up 29.4% in 2020

Next Post

CMS: Marketplace enrollment since Feb. 15 surpasses 2 million

Related Posts
Total
0
Share